Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $13.71.

Several analysts recently weighed in on HUMA shares. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Wednesday, March 26th. Finally, Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th.

Humacyte Trading Down 6.9 %

NASDAQ HUMA opened at $1.35 on Friday. The stock has a 50-day moving average of $3.31 and a 200-day moving average of $4.37. Humacyte has a 1-year low of $1.30 and a 1-year high of $9.97. The firm has a market cap of $169.91 million, a PE ratio of -1.01 and a beta of 1.36.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analysts’ expectations of $0.64 million. As a group, equities research analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Humacyte

Several institutional investors have recently added to or reduced their stakes in HUMA. Vontobel Holding Ltd. bought a new stake in shares of Humacyte in the fourth quarter valued at about $50,000. Petros Family Wealth LLC purchased a new position in shares of Humacyte during the 4th quarter valued at about $50,000. Syon Capital LLC purchased a new position in shares of Humacyte during the 4th quarter valued at approximately $54,000. Brookstone Capital Management purchased a new position in shares of Humacyte in the 4th quarter valued at about $56,000. Finally, ACT Wealth Management LLC acquired a new position in Humacyte in the 4th quarter worth about $57,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.